Noor Sahibzadi Mahrukh, Abuazzam Farah, Mathew Roy, Zhang Zhiwei, Abdipour Amir, Norouzi Sayna
Department of Nephrology, Loma Linda University, Loma Linda, CA, United States.
Front Nephrol. 2023 May 23;3:1175088. doi: 10.3389/fneph.2023.1175088. eCollection 2023.
IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide. Recently, there have been multiple advances in the understanding of IgAN pathophysiology and therapeutic options. Despite the advent of new treatment options, individual risk stratification of the disease course and choosing the best treatment strategy for the patient remains challenging. A multitude of clinical trials is ongoing, opening multiple opportunities for enrollment. In this brief review we discuss the current approach to the management of IgAN and highlight the ongoing clinical trials.
IgA肾病（IgAN）是全球原发性肾小球肾炎最常见的形式。最近，在IgA肾病病理生理学和治疗选择的理解方面有了多项进展。尽管出现了新的治疗选择，但对疾病进程进行个体风险分层并为患者选择最佳治疗策略仍然具有挑战性。大量临床试验正在进行，为入组提供了多个机会。在这篇简短的综述中，我们讨论了IgA肾病的当前管理方法，并强调了正在进行的临床试验。
